Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that Shari Pilon-Thomas, Ph.D. from the Moffitt Cancer Center will present the abstract titled “Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma,” at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting in two time slots on Saturday, November 8: 12:30 pm - 2:00 pm and 6:00 pm - 7:30 pm.
Help employers find you! Check out all the jobs and post your resume.
